Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part voluntarily and are able to sign and date a consent form before any study procedures begin, and who are able to complete the study as required
- People who are 50 years of age or older at the time of screening
- People who have been diagnosed with a specific type of age-related macular degeneration (wet AMD) in the eye being studied, as confirmed by the lead doctor
- People who have active abnormal blood vessel growth in the eye being studied, related to age-related macular degeneration
- People whose wet AMD has shown a positive response to anti-VEGF treatment (a type of eye injection commonly used for this condition), as assessed by the lead doctor before the study begins
Who may not be able to join:
- People who have an active infection or active inflammation in or around the eye being studied at the start of the study (for example, infections affecting the surface or interior of the eye)
- People who have a tear in a specific layer of tissue at the back of the eye being studied, detected at screening
- People who currently have bleeding in the gel-like part of the eye being studied, or who have had such bleeding within the 4 weeks before the study starts
- People who have any condition that, in the opinion of the lead doctor, may limit how much vision could improve in the eye being studied
- People who have a history of the retina detaching, or who have an active retinal detachment, in the eye being studied
- People who have previously received any form of gene therapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 18616737445
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Characteristics of dose limiting toxicities (DLTs); Type, severity, and incidence of ocular and systemic adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.